From the Laboratory for Ocular Cell Biology, Center for Applied Biotechnology and Molecular Medicine, University of Zurich, Zurich, Switzerland (FH, EAT-N); ELZA Institute, Dietikon/Zurich, Switzerland (FH, EAT-N, MH, NLH); the Faculty of Medicine, University of Geneva, Geneva, Switzerland (FH); the Department of Ophthalmology, University of Southern California, Los Angeles, California (FH); the Department of Ophthalmology, Wenzhou Medical University, Wenzhou, China (FH); EHC Centre Médical du Simplon, Renens, Switzerland (OR); and Federal University of São Paulo, Paulista School of Medicine, Department of Ophthalmology and Visual Sciences, São Paulo, Brazil (EAT-N).
Supported by Light for Sight Foundation, Zurich, Switzerland, and Velux Stiftung, Zurich, Switzerland.
Dr. Farhad Hafezi holds a patent on a UV light source (PCT/CH 2012/000090). Dr. Nikki Hafezi is CEO of EMAGine AG, a company producing a CXL device. The remaining authors have no financial or proprietary interest in the materials presented herein.
Study concept and design (FH); data collection (OR, EAT-N, NLH); analysis and interpretation of data (FH, OR, EAT-N, MH, NLH); writing the manuscript (FH, MH); critical revision of the manuscript (FH, OR, EAT-N, MH, NLH); supervision (FH)
Correspondence: Farhad Hafezi, MD, PhD, ELZA Institute, Webereistrasse 2 8953, Dietikon/Zurich, Switzerland. Email: